![Robert J. Bechard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert J. Bechard
Plus aucun poste en cours
Profil
Robert J.
Bechard is Chief Executive Officer at B3 Pharma, Inc. since 2025.
Mr. Bechard is Vice President-Corporate Development at IntelGenx Corp.
since 2016.
Former roles include Executive VP-Corporate Development & Licensing at Tetra Bio-Pharma, Inc. from 2018 to 2020, Chief Business Officer at Aronnax International, Inc. from 2014 to 2016, Managing Partner at RBC Capital Partners Ltd. from 1998 to 2009, Senior Member at RBC Life Sciences, Inc., and Director positions at Angiogenix, Inc., Conforma Therapeutics Corp., Cognetix, Inc., Viron Therapeutics, Inc., and Foragen Technologies Management, Inc. Education includes an MBA from Concordia University, undergraduate studies at the University of New Brunswick, and graduate studies at the London School of Economics & Political Science.
Postes actifs de Robert J. Bechard
| Sociétés | Poste | Début |
|---|---|---|
Intelgenx Corp.
 Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Develops oral-controlled release pharmaceutical products | Corporate Officer/Principal | 18/01/2016 |
Anciens postes connus de Robert J. Bechard
| Sociétés | Poste | Fin |
|---|---|---|
| TETRA BIO-PHARMA INC. | Corporate Officer/Principal | 01/05/2020 |
Aronnax International, Inc.
 Aronnax International, Inc. BiotechnologyHealth Technology Provides pre-clinical drug discovery and development services | Corporate Officer/Principal | 01/01/2016 |
RBC Capital Partners Ltd.
 RBC Capital Partners Ltd. Investment ManagersFinance RBC Capital Partners invests in companies located in US and Canada with historical stable cash flows, experienced management and competitive advantages. The fund targets companies operating in the fields of growth manufacturing, business services, consumer products, restaurants, retail, and oil & gas, IT and healthcare services. It provides financing for acquisitions, financial sponsor buyouts, shareholder buyouts, management buyouts, senior debt relief, growth capital requirements with an investment size in the range of $3 - $20 million, an EBITDA up to $3 million and an Enterprise Value greater than $10 million. | Private Equity Investor | 01/02/2009 |
Foragen Technologies Management, Inc.
 Foragen Technologies Management, Inc. Investment ManagersFinance Foragen Technologies Management invests in seed and early-stage, advanced agricultural technologies in Canada. | Corporate Officer/Principal | 01/11/2008 |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic solutions for chronic vascular diseases | Directeur/Membre du Conseil | 06/03/2008 |
Formation de Robert J. Bechard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
44
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
RBC Life Sciences, Inc.
 RBC Life Sciences, Inc. Pharmaceuticals: OtherHealth Technology Markets and distributes nutritional supplements & personal care products | Health Technology |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic solutions for chronic vascular diseases | Health Technology |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. BiotechnologyHealth Technology Designs and develops drugs for treatment of cancer | Health Technology |
Tetra Bio-Pharma, Inc.
 Tetra Bio-Pharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development and growing pipeline of biopharmaceuticals, natural health and veterinary products | Health Technology |
RBC Capital Partners Ltd.
RBC Capital Partners Ltd. Investment ManagersFinance RBC Capital Partners invests in companies located in US and Canada with historical stable cash flows, experienced management and competitive advantages. The fund targets companies operating in the fields of growth manufacturing, business services, consumer products, restaurants, retail, and oil & gas, IT and healthcare services. It provides financing for acquisitions, financial sponsor buyouts, shareholder buyouts, management buyouts, senior debt relief, growth capital requirements with an investment size in the range of $3 - $20 million, an EBITDA up to $3 million and an Enterprise Value greater than $10 million. | Finance |
Cognetix, Inc.
 Cognetix, Inc. Drugstore ChainsRetail Trade Discovers and develops drugs | Retail Trade |
Foragen Technologies Management, Inc.
Foragen Technologies Management, Inc. Investment ManagersFinance Foragen Technologies Management invests in seed and early-stage, advanced agricultural technologies in Canada. | Finance |
Concordia University
 Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of New Brunswick
 University of New Brunswick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London School of Economics & Political Science
 London School of Economics & Political Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel therapeutics for inflammatory disorders | Health Technology |
Intelgenx Corp.
Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Develops oral-controlled release pharmaceutical products | Health Technology |
Aronnax International, Inc.
Aronnax International, Inc. BiotechnologyHealth Technology Provides pre-clinical drug discovery and development services | Health Technology |
